AstraZeneca sells Atacand rights to Cheplapharm
admin 24th July 2018 Uncategorised 0AstraZeneca is selling rights to its heart failure and hypertension brand Atacand in Europe, in a move that it says will expand its commercial potential in 28 countries.
More: AstraZeneca sells Atacand rights to Cheplapharm
Source: News